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OBJECTIVE: Cardiac syndrome X is characterized by angina-like chest pain, a positive stress test, and normal coronary
arteries. A patient’s mean platelet volume, which potentially reflects platelet function and activity, is associated
with coronary atherosclerosis and endothelial dysfunction. The aim of the present study was to evaluate the mean
platelet volumes of patients with cardiac syndrome X, those with coronary artery disease and normal subjects.
METHODS: Two hundred thirty-six subjects (76 patients with cardiac syndrome X, 78 patients with coronary artery
disease, and 82 controls) were enrolled in the study. All of the subjects were evaluated with a detailed medical
history, physical examination, and biochemical analyses. The mean platelet volumes were compared between the
three groups.
RESULTS: The mean platelet volumes in the patients with cardiac syndrome X and with coronary artery disease were
significantly higher than those that were observed in the control group. There were no significant differences in the
mean platelet volumes between the cardiac syndrome X and the coronary artery disease groups.
CONCLUSION: We have established that patients with cardiac syndrome X and coronary artery disease exhibit
higher mean platelet volumes compared to controls. Patients with cardiac syndrome X exhibited higher mean
platelet volumes compared to the controls, reflecting the presence of subclinical atherosclerosis. These findings
suggest that, in addition to endothelial dysfunction, the presence of atherosclerosis may also contribute to the
etiopathogenesis of cardiac syndrome X.
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INTRODUCTION
Cardiac syndrome X (CSX) is a clinical entity that must be
distinguished from angina pectoris, the latter of which is due
to typical obstructive coronary heart disease. CSX has the
following three characteristic features: (i) angina or angina-
like chest pain with exertion; (ii) ST segment depression that
can be induced by treadmill exercise testing, or alternatively, a
pathological thallium scan with normal coronary arteriogra-
phy; and (iii) no spontaneous or inducible epicardial coronary
artery spasm upon ergonovine or acetylcholine provocation
(1). Several investigations have demonstrated that, despite
normal coronary vessels, patients with CSX exhibit electro-
cardiographic as well as metabolic evidence of myocardial
ischemia. Hence, the term ‘‘syndrome X’’ was first introduced
by Kemp in 1973 to define this clinical entity (2). In addition,
noncardiac causes of chest pain (e.g., esophageal disorders)
or psychiatric conditions (e.g., panic disorder) should be
excluded before CSX is diagnosed. Although the exact
mechanism by which CSX develops, remains unclear, silent
atherosclerosis and endothelial vasomotor dysfunction have
been suggested as possible contributing factors.
The mean platelet volume (MPV) is an indicator of platelet
activation, which is central to processes that are involved in
coronary heart disease pathophysiology (3). The MPV is
one of the platelet function indices that reflect the platelet
production rate and platelet stimulation. Elevated MPVs are
reported in cardiovascular diseases (4). However, as there are
few data regarding the relationship between MPV and CSX,
this study was designed to compare the MPVs of patients
with CSX, patients with CAD, and of normal controls.
METHODS
Patients
Twenty-eight hundred patients who had undergone
coronary angiography between Jan 2010 and May 2011 in
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a tertiary referral center were retrospectively examined.
Two hundred thirty-six patients were enrolled in the study
and were divided into three groups. The CSX group
consisted of 76 subjects (37 men and 39 women, mean age:
48.2¡4.8 years). The diagnosis of CSX was based on the
presence of a typical exercise-induced angina pectoris that
was associated with either (i) transient ischemic ST segment
depression ($1 mm) during the treadmill exercise test (31
patients) or (ii) a reversible perfusion defect on myocardial
perfusion scintigraphy (45 patients). Also required for a
diagnosis were angiographically normal coronary arteries in
the absence of coronary artery spasm (as determined by a
hyperventilation maneuver). The CAD group consisted of 78
subjects (38 men and 40 women, mean age: 48.3¡5.1 years)
with CAD, which was defined as $50% stenosis in a
minimum of one coronary artery. The control group consisted
of 82 age- and sex-matched individuals (40 men and 42
women, mean age: 47.2¡6.0 years) who presented with (i)
anginal chest pain, (ii) a normal coronary angiography, and
(iii) no ischemia on myocardial perfusion scintigraphy or
during the treadmill exercise test. Written informed consent
was obtained from all of the participants prior to enrollment.
The Institutional Ethics Committee approved the study
protocol, and the study was conducted in accordance with
the Declaration of Helsinki. All of the subjects were evaluated
with a detailed medical history, physical examination
and biochemical analysis. Special emphasis was placed on
cardiovascular risk factors and comorbid conditions. The
blood samples were analyzed for levels of low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol
and triglycerides (Beckman Coulter Syncron LX 20, Beckman
Coulter, Brea, CA, USA). All of the subjects were questioned
regarding cardiovascular drug use, smoking habits and
alcohol consumption. All of the subjects underwent trans-
thoracic echocardiography for structural heart disease. The
image acquisition was performed when the subject was in the
left lateral decubitus position. The images were obtained
using a Vingmed System Vivid 7 (GE Vingmed Ultrasound,
Horten, Norway), which was equipped with a standard two-
dimensional transducer.
The exclusion criteria included the following: refusal to
participate in the study and presence of hypertension,
diabetes mellitus, left ventricular dysfunction (left ventri-
cular ejection fraction ,50%) or hypertrophy, unstable
ischemic conditions (unstable angina pectoris and myocar-
dial infarction), valvular heart disease, congenital heart
disease, any observed abnormality in thyroid function tests,
renal or hepatic dysfunction (creatinine .1.2 mg/dl, aspar-
tate aminotransferase and alanine transaminase levels that
were higher than double the upper limits of normal,
respectively), inflammatory diseases, and any medication
that could affect the MPV.
Cardiac catheterization
The coronary angiograms were performed with a femoral
approach using the Judkins technique, without the use of
nitroglycerin, adenosine or calcium channel blockers.
Following the appropriate patient preparation, all of the
patients in the study population underwent elective coronary
artery angiography using the Siemens Axiom Artis DFC
(Siemens Medical Solutions, Erlangen, Germany). All of the
angiograms were evaluated by two experienced physicians
who were blinded to the study subjects’ group assignments.
The coronary angiograms were judged with regard to a
smooth appearance, luminal wall irregularities, epicardial
local or diffuse caliber reduction or stenosis. The coronary
arteries were classified as normal on the basis of visual
assessment of the absence of any luminal irregularities. To
exclude the possibility of coronary artery vasospasm, the
patients who exhibited normal coronary anatomy underwent
a hyperventilation test during the coronary arteriography.
The hyperventilation test was performed by asking the
patients to breathe rapidly and deeply for 5 minutes.
Biochemical measurements
The blood samples were withdrawn without stasis on the
morning of the day prior to the coronary angiography and
following a fasting period of 12 hours. The glucose, creatinine,
and lipid profiles were determined using standard methods.
For all of the groups, we measured the MPV from the blood
samples that were obtained following the venipuncture. The
blood was collected in tripotassium EDTA (7.2 mg) tubes. We
analyzed the blood samples of all of the groups using an
automatic blood counter after two hours of venipuncture.
This period of time was waited to allow for the stabilization of
platelet shape changes (Sysmex SE 9500, Roche).
Statistical analyses
The continuous variables are reported as the mean¡
standard deviation, whereas the categorical variables were
defined as percentages. The data were tested for normal
distributions using the Kolmogorov–Smirnov test. To com-
pare the continuous variables, a one-way analysis of variance
test or a Kruskal–Wallis test was used, as appropriate. When
significant differences were observed between the three
groups based on the post hoc analyses, either the Tukey or
the Mann–Whitney U tests were used to determine the
differences between the groups. A Chi-squared test was used
to compare the categorical variables. Statistical significance
was defined as p,0.05. The Statistical Package for the Social
Sciences statistical software package version 15 for Windows
(Statistical Package for the Social Sciences, Chicago, IL, USA)
was used for the statistical analyses.
RESULTS
The primary characteristics of the study population are
given in Table 1. There were no statistically significant
differences between the three groups with respect to age,
sex, smoking, or alcohol consumption (p.0.05). The body
mass indexes, lipid profiles and fasting glucose levels did
not differ between the three groups. Likewise, the labora-
tory characteristics of all of the groups were not significantly
different (Table 1). There were no statistically significant
differences in the MPV measurements between the CSX
and the CAD groups (p= 0.18) (Figure 1). The MPV was
significantly higher in both the CSX and CAD groups
compared with the control group (p,0.01) (Figure 1).
DISCUSSION
In the present study, we demonstrate that the MPV was
significantly increased in both CSX and CAD groups
compared with controls. These results may indicate that
elevated serum MPVs are associated with CSX-associated
atherosclerosis.
The pathophysiology of CSX has not been clearly identi-
fied, although multiple abnormalities, including abnormal
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coronary flow reserve, insulin resistance, abnormal auto-
nomic control, enhanced sodium hydrogen exchange activity,
abnormal cardiac sensitivity, and microvascular spasm
have been reported (5). All of these abnormalities may be
associated with endothelial dysfunction. Therefore, it is
unsurprising that the current hypotheses for the etiology of
CSX focus on the vascular endothelium and the biological
properties of arterial walls. The commonly accepted explana-
tion for the role of the vasculature in CSX includes general-
ized endothelial dysfunction, inflammation, and increased
pain sensitivity.
Platelets play an important role in the pathogenesis,
morbidity, and mortality of acute coronary syndromes (6).
Platelet function can be affected by several factors, such as
platelet count, size, density, platelet age, a higher granule
count, and adhesion receptor expression, as well as a higher
mean platelet volume. The MPV appears to correlate more
closely with platelet function than does platelet count alone
(7). In previous reports, the following methods were used to
analyze platelet activation: optical aggregometry, platelet
function analysis using a PFA-100 system, platelet reactivity
tests, platelet aggregate ratio measurements, flow cytometry
and thromboxane B2 generation tests (8). All of these tests
are of limited use due to complex preanalytic factors,
reduced specificity and poor reproducibility. MPV is a
simple marker that does not require advanced or expensive
technology. However, the MPV may reflect platelet function
and activity and may indirectly reflect platelet production
and stimulation; therefore, elevated MPVs values may
indicate cardiovascular diseases. Increased MPV may be
due to the body’s use of small platelets during acute
ischemia (9). Thus, MPV has become a prognostic factor in
coronary heart disease and may eventually be accepted as a
parameter of platelet activity (10). In addition, several
Table 1 - The baseline clinical and biochemical characteristics of the study groups.
CSX group
(n=76)
CAD group
(n=78)
Control group
(n=82) p-value
Age, yrs
Gender (M), n (%)
Active smokers, %
Alcohol consumption, %
BMI (kg/m2)
Hemoglobin (g/dl)
Fasting glucose (mg/dl)
LDL cholesterol (mg/dl)
HDL cholesterol (mg/dl)
Triglycerides (mg/dl)
Creatinine (mg/dl)
Urea (mg/dl)
48.2¡4.8
37 (48)
26.1
12.1
26.9¡6.5
13.8¡1.55
93¡9
119.0¡28.1
43.1¡9.1
148.6¡56.8
1.02¡0.13
32.8¡5.0
48.3¡5.1
38 (48)
24.5
10.8
25.1¡5.8
13.4¡1.32
101¡12
113.0¡33.3
36.9¡6.9
155.6¡71.9
0.97¡0.22
34.9¡8.8
47.2¡6.0
40 (48)
27.2
9.8
27.2¡6.0
14.0¡1.21
100¡6
114.7¡22.9
41.3¡7.1
142.8¡58.8
0.96¡0.17
33.1¡8.2
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
M: Male; BMI: Body mass index; LDL: Low density lipoprotein; HDL: High density lipoprotein; CSX: Coronary syndrome X; CAD: Coronary artery disease
The values are mean¡SD.
Figure 1 - The MPV measurements of the three groups. There were no statistically significant differences in the MPV measurements
between the CSX and the CAD groups (p=0.18). Compared with the controls, the patients with either CSX or CAD exhibited
significantly increased MPVs (p,0.01).
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reports have demonstrated that there is a close relationship
between MPV and cardiovascular risk factors, including
impaired fasting glucose levels, diabetes mellitus, hyperten-
sion, hypercholesterolemia, obesity, and metabolic syn-
drome (11–13). It has been reported that elevated MPVs
are associated with cardiovascular diseases (14). It is also
known that increased platelet activation and aggregation
are closely related to cardiovascular complications (10).
The origin of CSX is still debated; however, endothelial
dysfunction, leading to a reduced coronary microvascular
dilatory response and increased coronary resistance, are
thought to play important roles. Abnormal subendocardial
perfusion was detected using magnetic resonance imaging
in patients with CSX (1). Cox et al. empirically demonstrated
the presence of endothelial dysfunction and subangio-
graphic atheroma in patients with CSX (15). Abnormal
coronary arteries with atheromatous plaques and intimal
thickening have been observed in intravascular ultrasono-
graphic studies of patients with CSX (15,16). Therefore, the
ethiopathogenesis of CSX may be similar to that of CAD. We
therefore investigated the relationship between CSX and
MPV and demonstrated a significant association between
the two. In contrast to the present study, Cay et al. observed
significantly higher MPVs in patients with CSX compared to
those of patients with stable angina; however, the inter-
pretation of this previous study is limited by its lack of a
control group (17). In addition, the exclusion criteria were
not as strict as those that were adopted in the present study.
Furthermore, we excluded patients with hypertension, left
ventricular dysfunction (left ventricular ejection fraction
,50%) and hypertrophy, valvular heart disease, congenital
heart disease, thyroid disease, and inflammatory diseases.
Lastly, differences in the patient selection process may
explain the discordant results between these two studies.
The control group in the present study was selected based
on complaints of anginal chest pain and a normal coronary
angiography. Further inclusion criteria for the control group
included the absence of ischemia both on myocardial
perfusion scintigraphy and during the treadmill exercise
test. Therefore, our study was designed to investigate the
MPVs of patients with CSX or CAD compared with those of
normal subjects.
The primary limitation of our study was the compara-
tively small size of the study population. Another limitation
was the possibility of underlying coronary artery spasm in
patients with CSX, which was excluded using a hyperven-
tilation test, although the ergonovine test would have been
the ideal test in this contest. Lastly, intravascular ultrasound
(IVUS) provides more precise values than does coronary
angiography and is more sensitive with respect to detecting
and determining the distribution of coronary atherosclerotic
plaques in the vessel lumen and throughout the wall.
However, we were unable to perform IVUS in this study.
In conclusion, no statistically significant differences were
observed with respect to MPV measurements between the
CSX and the CAD groups. Relative to the controls, the MPV
was significantly higher in patients with either CSX or CAD.
These results suggest that elevated MPVs may participate in
the pathogenesis of CSX. Prospective, placebo-controlled
studies with large sample sizes that use multivariable
survival analyses and long-term follow-up periods are
required for the clinical evaluation of the prognostic value
of increased MPV in patients with CSX.
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